ALPMY News Alert Astellas Pharma Inc (ALPMY) 15.4600 02/13/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 12:00 AM

Astellas Pharma Inc (ALPMY) 15.4600 $ALPMY

Why Shares of Cytokinetics Incorporated Skyrocketed
George Budwell, The Motley Fool - Motley Fool - Fri Feb 13, 11:44AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What : Shares of the clinical-stage biopharma Cytokinetics ...
CYTK: 7.78 (+1.29), AMGN: 153.48 (+0.30)

Medivation and Astellas Report TERRAIN Data on Xtandi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 23, 3:20PM CST
Medivation Inc. (MDVN) and partner Astellas Pharma Inc.'s (ALPMY) Xtandi met the primary endpoint in a phase II study (TERRAIN) conducted in metastatic prostate cancer patients.
MDVN: 104.71 (+0.67), AZN: 69.96 (+0.20), AMGN: 153.48 (+0.30)

Ad Comm gives thumbs up to Astellas anti-fungal
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 2:13PM CST

Ad Comm meets today to review Astellas NDA for antifungal med
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 7:51AM CST

Xtandi successful in Phase 2 study
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 7:34AM CST

MDVN: 104.71 (+0.67), AZN: 69.96 (+0.20)

Johnson & Johnson Overcomes Threats from Competitors, Delivers Solid Quarterly Results
Todd Campbell, The Motley Fool - Motley Fool - Tue Jan 20, 1:01PM CST
Source: Johnson & Johnson Despite two of Johnson & Johnson 's best-selling drugs facing stiffer competition, the company still managed to deliver encouraging sales and earnings during the fourth quarter. After adjusting for currency...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), GILD: 101.90 (+1.10), ABBV: 58.05 (+1.00)

Boehringer Ingelheim's OFEV cleared in Europe for IPF
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:26PM CST

AZN: 69.96 (+0.20), FGEN: 30.25 (+0.50), BMY: 60.04 (+0.56)

These 3 Biotechs Are Looking at a Happy New Year
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 31, 11:33AM CST
This healthcare edition of Industry Focus takes a look at three biotech stocks and why each company is positioned for a great performance in the coming year. If your portfolio could use some exposure to healthcare and biotechs, join the Fool's...
NFLX: 466.10 (+9.37), MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), AMZN: 381.83 (+4.66), JPM: 59.67 (+0.10), GILD: 101.90 (+1.10), AGIO: 118.55 (+0.11), AAPL: 127.08 (+0.62), XLRN: 38.02 (+0.07), CELG: 115.88 (+0.16)

Seeking Alpha's Biotech Weekly: AbbVie Slaps Gilead, Achillion's 'Nuc' Power, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Dec 26, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. What should the Seeking Alpha community be reading and writing about? Please leave...
MGNX: 34.09 (+0.10), CYTK: 7.78 (+1.29), JNJ: 99.62 (+1.18), ESRX: 84.90 (+0.40), ALNY: 95.54 (+1.67), GILD: 101.90 (+1.10), ACHN: 10.89 (-0.20), ABBV: 58.05 (+1.00), BMY: 60.04 (+0.56), ANIK: 41.30 (-0.17)

Cytokinetics Rises After Extending Astellas Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 4:10PM CST
Cytokinetics (CYTK) shares jumped after announcing an amendment to its collaboration with Astellas.
CYTK: 7.78 (+1.29), AMGN: 153.48 (+0.30), AFFX: 11.45 (+0.02)

Cytokinetics and Astellas expand partnership
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 7:28AM CST

CYTK: 7.78 (+1.29)

The Most Disappointing Clinical Failures in 2014
Motley Fool Staff - Motley Fool - Sun Dec 21, 6:32PM CST
Since roughly 90% of all clinical trials end in a failure, it isn't too shocking that 2014 boasted its fair share of clinical trial disappointments. But while failure is common and expected in the industry, some defeats were more disappointing than...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), AZN: 69.96 (+0.20), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), EXEL: 2.48 (+0.20)

3 Large Cap Biotech Stocks That Could Surprise Investors in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 21, 11:55AM CST
Source: Celgene Corp. The volatility that comes with investing in biotech stocks can test the patience of even the most risk-tolerant investor. Many investors may be better served focusing on companies with proven track records of success rather...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), CELG: 115.88 (+0.16)

These Biotech Stocks Are Growing Even Faster Than Gilead Sciences
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 21, 7:31AM CST
Thanks to billions of dollars in new revenue from recently launched hepatitis C drugs, Gilead Sciences sales surged 117% year over year during the third quarter. That's impressive growth by any measure, but investors might be surprised to learn...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18), PCYC: 163.28 (+0.23), GILD: 101.90 (+1.10)

The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?
Todd Campbell, The Motley Fool - Motley Fool - Fri Dec 19, 6:44AM CST
From Medicaid expansion to cancer drugs to minimally invasive treatment for heart disease, Industry Focus looks at the 10 top performers among large-cap healthcare stocks in 2014. There were some surprises on the list this year, with strong showings...
AGN: 229.49 (+1.87), MDVN: 104.71 (+0.67), CNC: 118.18 (-0.01), JNJ: 99.62 (+1.18), VRX: 167.00 (-0.50), ACT: 285.37 (+3.71), EW: 134.23 (+1.89), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)

Astellas-Medivation Reveal Data on Xtandi for Breast Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 2:00PM CST
Astellas Pharma Inc. (ALPMY) and Medivation announced the presentation of stage I and preliminary stage II data from a phase II study on Xtandi triple negative breast cancer.
MDVN: 104.71 (+0.67), LCI: 57.78 (-0.91), SCMP: 15.32 (+0.04)

Ironwood earns $15M milestone from Astellas
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 8:31AM CST

IRWD: 15.15 (-0.85)

AVEO Gains on Tivozanib Agreement with Ophthotech - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:20PM CST
AVEO Pharmaceuticals' (AVEO) shares gained around 10.9% ever since the company announced a deal with Ophthotech (OPHT).
OPHT: 51.11 (+0.12), AVEO: 0.84 (-0.06), AMAG: 41.49 (+0.23)

Should Johnson & Johnson Buy Medivation Inc.?
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 6:55AM CST
Source: Johnson & Johnson. Johnson & Johnson is losing the battle for prostate cancer market share to the far smaller Medivation , but that may not mean that J&J should step up and acquire the company. First, a little...
MDVN: 104.71 (+0.67), JNJ: 99.62 (+1.18)

FibroGen on deck for IPO
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:46PM CST

IPO: 24.00 (+0.09), BIS: 39.67 (-0.75), BIB: 141.30 (+2.39), AZN: 69.96 (+0.20), IBB: 323.46 (+3.04), FGEN: 30.25 (+0.50)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Zika Virus: A Surprising Ally in Brain Cancer Fight

Here’s something you don’t hear every day: using a virus that typically targets the brain not as a foe, but as a formidable ally in the war against glioblastoma. It’s a gutsy play by UP Oncolytics, a scrappy biotech outfit cradled within Rosalind Franklin University’s Helix 51 incubator. Risky Bet on a Known Adversary Glioblastoma—a real beast in the cancer...

Food Trends Tease: 2027 sofi™ Awards' 75 Finalists

The Specialty Food Scene Heats Up Today’s world doesn’t rest when it comes to innovation, and the same goes for the tantalizing realm of specialty foods. Hot off the press, the Specialty Food Association (SFA) just rolled out the red carpet for its 75 finalists in the 2027 sofi™ Awards. These are the future taste shapers set to take center stage at the Winter...

Steel Dynamics' Q3 2026: Record Shipments Boost Profits

Steel Dynamics Shatters Records in Q3 2026 If there was any doubt about Steel Dynamics' ability to ride the waves in the steel and aluminum market, the third quarter of 2026 put that to rest. With a record-breaking 3.8 million tons of steel shipped and net sales reaching a steep $6.5 billion, this isn't just business as usual—it's smashing their own ceiling. Operating...

Understanding Truck Accident Settlements in Memphis

Delving into Truck Accident Settlement Timelines Out there in Memphis, timing a truck accident settlement isn't exactly like clockwork work. When it comes to getting your compensation, the timeline varies as widely as a duck hunting trip—sometimes you come home with a basketful, sometimes it’s empty. It might be a quick couple of months or drag on past a year, and...

AAI Rolls Out Agency Gauge: AI-Driven Insights Platform

Bringing Artificial Intelligence to the Insurance Table Affordable American Insurance (AAI) is shaking things up in the insurance world with their new tool, Agency Gauge. Picture this: you're running an independent agency, neck-deep in data, and this AI-powered marvel swoops in and turns those confusing numbers into actionable business insights. It's like having a wise...

Cruise Planners Sets AI Benchmark in Travel Innovs

Unveiling the AI Arsenal of Cruise Planners Alright, listen up, folks. When you think about travel and tech, Cruise Planners ain't just dipping a toe—they're cannonballing right in, splashing everyone around with their shiny new AI tricks. Twenty-three. That's how many innovations they're flaunting this year. It's like they're running a tech marathon, and boy, are they...

OppFi Readies Q3 Earnings; Investors Eye Financials

What's Unfolding at OppFi? Mark your calendars, folks. October 28th is the day OppFi (NYSE: OPFI) pulls the curtain back on its third-quarter 2026 earnings. For the uninitiated, we're talking about a tech-driven finance platform that's been making waves by providing financial solutions for everyday Americans. And you bet we're all ears for what those numbers say. Details...

Cancer Memoir Shows Healing Beyond Medicine

Confronting the Unfathomable Out of the North Carolina mountains comes a story that defies expectations—a pastor and farmer named Mark Heisey, who faced the no-holds-barred trials of stage IV-B lymphoma. Now, I'll shoot you straight: this isn't your run-of-the-mill self-help guide or a clinical breakdown of battling cancer. His new memoir dives into the personal and...

Ruth E. Carter Returns Home with Celebrated Exhibition

Ruth E. Carter’s Triumphant Return When a titan of the costume design world circles back to their roots, you know it’s bound to be something special. Ruth E. Carter, who has swapped needles and threads for Oscars (twice, mind you), is making a return to Hampton University, paying homage to the very soil that sowed her artistic seeds. Ain't that a capstone of a career...

Art Print Paper: Finding the Perfect Match for Masterpieces

You ever stand in a gallery and notice how some art just lights up the room while others barely get a second glance? Well, a lot of that magic starts with an unsung hero—paper choice. I came across this bit from HelloNation diving into what makes paper selection a cornerstone for fine art prints. Now, I ain't an artist, but even a bruiser trader like me can see the...